Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Real-World Analysis Suggests Social Determinants of Health May Be Associated With Early Onset of CRC

June 18th 2025

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Paulus on Factors Contributing to Earlier Onset of CRC in Younger Patients

June 17th 2025

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

DPD Testing and Medication Dosage Adjustments in mCRC Patients

June 16th 2025

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

The Importance of Biomarker Testing in mCRC

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Five Under 5: Top Oncology Videos for the Week of 6/1

June 8th 2025

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

NCCN Adds 2 Tests to CRC Screening Guidelines

June 3rd 2025

The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.

Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer

June 1st 2025

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer

June 1st 2025

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC

May 31st 2025

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC

May 31st 2025

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC

May 31st 2025

Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.

ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer

May 31st 2025

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC

May 30th 2025

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC

May 30th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

Dr Haldar on the Future Directions for Evaluating NeoAg-VAX in Colorectal Cancer

May 27th 2025

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic CRC

May 20th 2025

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.